Company Overview - Agios Pharmaceuticals, Inc. is a biopharmaceutical company focused on therapies for rare hematologic diseases, utilizing expertise in cellular metabolism [6] - The company's strategy involves advancing innovative treatments from research to commercialization, targeting high unmet medical needs [6] - Agios has a pipeline anchored by PYRUKYND and ongoing clinical programs, aiming to establish a competitive position in the rare disease space [6] Financial Performance - As of February 17, 2026, Agios Pharmaceuticals has a market capitalization of $1.63 billion [4] - The company reported a total revenue of $54.03 million for the trailing twelve months (TTM) [4] - Agios posted a net income loss of $412.78 million for the TTM [4] - The stock price was $27.82, reflecting a 17% decline over the past year, underperforming the S&P 500's approximately 13% gain [8] Recent Developments - Commodore Capital sold all 2,338,287 shares of Agios Pharmaceuticals in the fourth quarter, resulting in a decrease of approximately $93.86 million in the position's quarter-end value [1][2] - The company experienced a significant stock price drop of 50% in one day following the Phase 3 RISE UP trial of mitapivat, which failed to reduce sickle cell pain crises [10] - Agios reported a net loss of $108 million in the fourth quarter, compared to a $96.5 million loss in the same quarter the previous year [10] Investment Context - The current investment climate in biotech is shifting towards momentum stocks, with Agios being perceived as underperforming due to execution challenges rather than a lack of assets [11] - The company's capital is concentrated in clinical-stage immunology names, with Agios positioned slightly outside this core theme [11]